Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Godavari Drugs Limited is a pharmaceutical manufacturer based in India, specializing in active pharmaceutical ingredients (APIs) and formulations. The company primarily serves the domestic market while also exporting to various international markets, leveraging its established supply chain and regulatory compliance capabilities.
Godavari Drugs generates revenue through the production and sale of APIs and finished pharmaceutical products, benefiting from cost efficiencies and established relationships with key clients. The company has moderate pricing power due to its regulatory compliance and quality assurance processes, which are critical in the pharmaceutical industry.
Regulatory approvals for new drugs and APIs
Changes in domestic and international pricing regulations
Market demand for generic drugs in emerging markets
Currency fluctuations affecting export revenues
Regulatory changes impacting drug approvals and pricing
Technological disruption in drug manufacturing processes
Increased competition from generic drug manufacturers
Potential market entry by larger multinational pharmaceutical companies
High debt levels relative to equity (Debt/Equity of 1.01)
Negative free cash flow indicating potential liquidity issues
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand can be affected by consumer spending and healthcare budgets.
Higher interest rates can increase the company's financing costs for capital expenditures, potentially impacting profitability and cash flow.
minimal - The company does not heavily rely on credit for operations, but higher interest rates could affect future financing options.
value - Investors may be drawn to the stock due to its low Price/Sales ratio and potential for recovery in margins.
moderate - The stock has shown volatility with a 1-Year Return of 22.6%, indicating potential for both gains and losses.
